Management Team

Management Team

Mesoblast has a highly experienced management team made up of individuals who have held senior positions in international pharmaceutical and biotechnology companies. This team is responsible for the strategic direction, operations and success of our company.

Silviu Itescu, MBBS, FRACP
Chief Executive Officer & Managing Director

Dr Itescu has served on Mesoblast's Board of Directors since the Company's founding in 2004, was Executive Director from 2007, and became Chief Executive Officer and Managing Director in 2011. Prior to founding Mesoblast in 2004, he established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. In 2011, he was named BioSpectrum Asia Person of the Year. He has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the Board of Directors of several publicly listed life sciences companies.

Silviu Itescu, MBBS, FRACP
Chief Executive Officer & Managing Director


Dr Itescu has served on Mesoblast's Board of Directors since the Company's founding in 2004, was Executive Director from 2007, and became Chief Executive Officer and Managing Director in 2011. Prior to founding Mesoblast in 2004, he established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbou... 

Paul Hodgkinson, MA (Hons), FCA
Chief Financial Officer

Mr Hodgkinson joined Mesoblast in 2014 as Chief Financial Officer. He has 16 years of international pharmaceutical experience in the areas of finance, strategic planning, business development and licensing, manufacturing and supply chain, and procurement. From 2011 through 2014, Mr Hodgkinson served as the Country Chief Financial Officer for the Novartis Australia and New Zealand, or ANZ, group of companies and divisions, which was comprised of Alcon, Sandoz, and the Novartis Vaccines and Diagnostics, Consumer Health, Animal Health, and Pharmaceuticals divisions. Previously he held a number of leadership roles with AstraZeneca in the UK, including Global Licensing Finance Director, before serving as CFO for AstraZeneca Australia from 2006-2011. Mr Hodgkinson is a member of the Institute of Chartered Accountants in Australia, is a Fellow of the Institute of Chartered Accountants of England and Wales and has a Masters in Engineering from Cambridge University. He has also undertaken executive leadership programs at the Harvard Business School and INSEAD.

Paul Hodgkinson, MA (Hons), FCA
Chief Financial Officer


Mr Hodgkinson joined Mesoblast in 2014 as Chief Financial Officer. He has 16 years of international pharmaceutical experience in the areas of finance, strategic planning, business development and licensing, manufacturing and supply chain, and procurement. From 2011 through 2014, Mr Hodgkinson served as the Country Chief Financial Officer for the Novartis Australia and New Zealand, or ANZ, group of companies and divisions, which was comprised of Alcon, Sandoz, and the Novartis Vaccines and Dia... 

Roger D. Brown, BA
Spinal Orthopedic Disorders

Prior to joining Mesoblast in 2009, Mr Brown served as the Divisional Vice President, Clinical, Regulatory and Quality for Abbott Laboratories’ Spine Division. He has over 20 years of regulatory, clinical, product development, quality and reimbursement experience dealing with a variety of technologies from physiological monitoring equipment to implantable and biological products. Mr Brown has also held clinical and regulatory roles at Axiomed Spine Corporation, Wright Medical Technology, CryoLife and Nellcor Puritan Bennett. He received a Bachelor of Arts from Missouri’s William Jewell College and completed coursework at Oxford University in England.

Roger D. Brown, BA
Spinal Orthopedic Disorders


Prior to joining Mesoblast in 2009, Mr Brown served as the Divisional Vice President, Clinical, Regulatory and Quality for Abbott Laboratories’ Spine Division. He has over 20 years of regulatory, clinical, product development, quality and reimbursement experience dealing with a variety of technologies from physiological monitoring equipment to implantable and biological products. Mr Brown has also held clinical and regulatory roles at Axiomed Spine Corporation, Wright Medical Technology, Cryo... 

Lee Golden, MD
Cardiovascular Diseases

Dr Golden, who is a trained interventional cardiologist with over 20 years of clinical and industry experience, joined Mesoblast in 2011. He started his industry career at Pfizer as a Medical Director on the global Lipitor team, where his responsibilities included overseeing multinational cardiovascular trials. Dr Golden has extensive experience across several therapeutic areas, with orphan diseases, and with global drug development of both small molecules and biologics. Prior to joining Mesoblast, he was the Global Therapeutic Head for Cardiovascular and Hematology at Eisai where he managed multiple development programs from preclinical through to commercialization.

Lee Golden, MD
Cardiovascular Diseases


Dr Golden, who is a trained interventional cardiologist with over 20 years of clinical and industry experience, joined Mesoblast in 2011. He started his industry career at Pfizer as a Medical Director on the global Lipitor team, where his responsibilities included overseeing multinational cardiovascular trials. Dr Golden has extensive experience across several therapeutic areas, with orphan diseases, and with global drug development of both small molecules and biologics. Prior to joining Meso... 

Peter Howard, BSc, LLB (Hons)
Corporate Executive & General Counsel

Mr Howard has been integrally involved with Mesoblast since its inception in 2004, when he played a critical role in the corporate structuring and listing of Mesoblast on the ASX. More generally, he has extensive experience with many biopharmaceutical firms and major research institutions, covering public listings, private financings, strategic, licensing, intellectual property and mergers and acquisition activities. Mr Howard has done so in several roles, including as a partner at a major law firm, entrepreneur, director and senior executive.

Peter Howard, BSc, LLB (Hons)
Corporate Executive & General Counsel


Mr Howard has been integrally involved with Mesoblast since its inception in 2004, when he played a critical role in the corporate structuring and listing of Mesoblast on the ASX. More generally, he has extensive experience with many biopharmaceutical firms and major research institutions, covering public listings, private financings, strategic, licensing, intellectual property and mergers and acquisition activities. Mr Howard has done so in several roles, including as a partner at a major la... 

Sue MacLeman, BPharm, MMktg, MLaw, FACPP, FAICD
Commercial

Mrs MacLeman has served as our global Head of Commercial since 2014 and previously as SVP Corporate from 2011 – 2013. She has more than 20 years’ experience as a pharmaceutical executive with roles in corporate, medical, marketing, business development, and sales management at Schering-Plough Corporation (now Merck), Amgen Inc. and Bristol-Myers Squibb. Mrs MacLeman also served as CEO and Board member of EQiTX Ltd, and Benitec Biopharma Ltd, and CEO of Progen Pharmaceuticals Ltd. She is currently a non-executive director at Reproductive Health Sciences Ltd.

Sue MacLeman, BPharm, MMktg, MLaw, FACPP, FAICD
Commercial


Mrs MacLeman has served as our global Head of Commercial since 2014 and previously as SVP Corporate from 2011 – 2013. She has more than 20 years’ experience as a pharmaceutical executive with roles in corporate, medical, marketing, business development, and sales management at Schering-Plough Corporation (now Merck), Amgen Inc. and Bristol-Myers Squibb. Mrs MacLeman also served as CEO and Board member of EQiTX Ltd, and Benitec Biopharma Ltd, and CEO of Progen Pharmaceuticals Ltd. She is curre... 

John McMannis, PhD
Manufacturing

Dr McMannis has 27 years of experience in clinical cellular therapy trials in both academic and commercial environments. Before joining Mesoblast in 2011, he served at the University of Texas MD Anderson Cancer Center as a Professor of Medicine from 1999 to 2011, and as the Director of the Cell Therapy Laboratory from 1999 to 2011, and as the Technical Director of the Cord Blood Bank from 2008 to 2011. Before his tenure at the University of Texas MD Anderson Cancer Center, Dr McMannis was a Senior Director Technical Affairs at the Immunotherapy Division of Baxter and Therapy Scientist at COBE BCT (now Terumo BCT). He has served on the scientific advisory boards at BioSafe SA, Biolife Solutions, Inc., and General Electric and on the board of directors for the American Association of Blood Banks, or AABB, and the National Marrow Donor Program, or NMDP, which operates the “Be the Match” donor program.

John McMannis, PhD
Manufacturing


Dr McMannis has 27 years of experience in clinical cellular therapy trials in both academic and commercial environments. Before joining Mesoblast in 2011, he served at the University of Texas MD Anderson Cancer Center as a Professor of Medicine from 1999 to 2011, and as the Director of the Cell Therapy Laboratory from 1999 to 2011, and as the Technical Director of the Cord Blood Bank from 2008 to 2011. Before his tenure at the University of Texas MD Anderson Cancer Center, Dr McMannis was a S... 

Julie Meldrum, Inv Rel (AIRA)
Global Corporate Communications

Ms Meldrum joined Mesoblast in 2004. She has deep and diverse experience as a corporate communications strategist, European foreign correspondent, political and business reporter and television and radio producer. Ms Meldrum also served as a senior diplomat for 14 years promoting Australian policies and industries in the key markets of Japan, Hong Kong and Indonesia and has advised Prime Ministers, Cabinet Ministers and business leaders. She has been the recipient of the League of American Communication Professionals Gold Magellan Award, the United Nations Media Peace Prize for Radio, was a Governor of the Foreign Correspondents’ Club in Hong Kong and a Director of Australian Doctors International. Ms Meldrum is co-chair of the Washington DC-based Alliance of Regenerative Medicine’s Communications and Education Committee.

Julie Meldrum, Inv Rel (AIRA)
Global Corporate Communications


Ms Meldrum joined Mesoblast in 2004. She has deep and diverse experience as a corporate communications strategist, European foreign correspondent, political and business reporter and television and radio producer. Ms Meldrum also served as a senior diplomat for 14 years promoting Australian policies and industries in the key markets of Japan, Hong Kong and Indonesia and has advised Prime Ministers, Cabinet Ministers and business leaders. She has been the recipient of the League of American Co... 

Michael  Schuster, MS, MBA
Investor Relations, New Product & Technology Evaluation

Mr Schuster, who joined Mesoblast in 2004, has been the head of the Company’s investor relations outreach program since 2013 and was part of the founding executive team at both Mesoblast Limited and Angioblast Systems, Inc. He was Executive Vice President of Global Therapeutic Programs from 2010 to 2013 and was the Director of Business Development and Vice President of Operations from 2004 to 2010. He holds an undergraduate degree in science from Tufts University, a Master’s degree in Immunology & Microbiology from New York Medical College, and a MBA from Fordham University in New York.

Michael  Schuster, MS, MBA
Investor Relations, New Product & Technology Evaluation


Mr Schuster, who joined Mesoblast in 2004, has been the head of the Company’s investor relations outreach program since 2013 and was part of the founding executive team at both Mesoblast Limited and Angioblast Systems, Inc. He was Executive Vice President of Global Therapeutic Programs from 2010 to 2013 and was the Director of Business Development and Vice President of Operations from 2004 to 2010. He holds an undergraduate degree in science from Tufts University, a Master’s degree in Immunol... 

Karen  Segal, PhD
Diabetes and Metabolic Diseases

Before joining Mesoblast in 2011, Dr Segal established herself as a senior academic investigator for more than 15 years in diabetes, metabolism and obesity at Columbia University's College of Physicians and Surgeons, Mount Sinai School of Medicine, and Weill Cornell Medical College. Prior to joining Mesoblast, she worked for 15 years in leadership roles at Hoffmann La Roche and at Sanofi-Aventis in global clinical development and medical affairs for programs in diabetes and metabolism.

Karen  Segal, PhD
Diabetes and Metabolic Diseases


Before joining Mesoblast in 2011, Dr Segal established herself as a senior academic investigator for more than 15 years in diabetes, metabolism and obesity at Columbia University's College of Physicians and Surgeons, Mount Sinai School of Medicine, and Weill Cornell Medical College. Prior to joining Mesoblast, she worked for 15 years in leadership roles at Hoffmann La Roche and at Sanofi-Aventis in global clinical development and medical affairs for programs in diabetes and metabolism.

... 
Paul  Simmons, PhD
Research and New Product Development

Prior to joining Mesoblast in 2011, Dr Simmons had nearly 30 years of experience in stem cell research, especially research in basic hematopoiesis and in precursor cells for the stromal system of the bone marrow. He served as President of the International Society of Stem Cell Research from 2006 to 2007. Dr Simmons held the C. Harold and Lorine G. Wallace Distinguished University Chair at the University of Texas Health from 2008 to 2011 and served as the inaugural Professor and Director of the Centre for Stem Cell Research at the Brown Foundation Institute of Molecular Medicine from 2006 to 2011. He is, or has served as, an associate editor, a member of the editorial board, or a reviewer on multiple scientific and medical journals including Experimental Hematology, Cytotherapy and Stem Cell Research, Cell Stem Cell, Stem Reports, Science and Nature.

Paul  Simmons, PhD
Research and New Product Development


Prior to joining Mesoblast in 2011, Dr Simmons had nearly 30 years of experience in stem cell research, especially research in basic hematopoiesis and in precursor cells for the stromal system of the bone marrow. He served as President of the International Society of Stem Cell Research from 2006 to 2007. Dr Simmons held the C. Harold and Lorine G. Wallace Distinguished University Chair at the University of Texas Health from 2008 to 2011 and served as the inaugural Professor and Director of th... 

Donna Skerrett, MD, MS
Chief Medical Officer

Dr Skerrett, who has more than 20 years of combined experience in transfusion medicine, cellular therapy, and transplantation, has held executive roles at Mesoblast since 2004. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Center in New York from 2004 to 2011, and served as Associate Director of Transfusion Medicine and Director of Stem Cell Facilities at Columbia University’s New York-Presbyterian Hospital from 1999 to 2004. Dr Skerrett has been an advisor to the New York State Department of Health on the Progenitor Cell Committee since 1989, Chair of the Governor’s Council on Blood and Transfusion Services since 2007, and serves on the Executive Committee of the Alliance for Regenerative Medicine. From 2004, she held roles at Mesoblast in clinical and regulatory affairs until she was appointed Chief Medical Officer in 2011.

Donna Skerrett, MD, MS
Chief Medical Officer


Dr Skerrett, who has more than 20 years of combined experience in transfusion medicine, cellular therapy, and transplantation, has held executive roles at Mesoblast since 2004. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Center in New York from 2004 to 2011, and served as Associate Director of Transfusion Medicine and Director of Stem Cell Facilities at Columbia University’s New York-Presbyterian Hospital from 1999 to 2004. Dr Skerrett has been an ad... 

Jonathan R. Symonds, CBE, BA, FCA
Corporate Finance & Strategy

Mr Symonds, who was Chief Financial Officer of Novartis AG from 2009 to 2013, became an advisor to Mesoblast in 2014. Prior to joining Novartis, Mr Symonds was a Partner and Managing Director of Goldman Sachs Group Inc (2007-2009), Chief Financial Officer of AstraZeneca plc (1997-2007) and a Partner of KPMG (1992-1997). In 2014, he was appointed an independent non-executive Director of HSBC Holdings plc and Chairman of HSBC’s European subsidiary, HSBC Bank plc. He is a non-executive Director of Genomics England Limited. Previous roles include non-executive Director of Diageo plc and Qinetiq plc., Chairman of the 100 Group of Finance Directors, Joint Chairman of the Business Tax Forum, board member of the Accounting Standards Board, and founder of the Oxford University Centre for Business Taxation Research, all in the United Kingdom. In 2007, Mr Symonds was awarded a Commander of the British Empire for service to industry.

Jonathan R. Symonds, CBE, BA, FCA
Corporate Finance & Strategy


Mr Symonds, who was Chief Financial Officer of Novartis AG from 2009 to 2013, became an advisor to Mesoblast in 2014. Prior to joining Novartis, Mr Symonds was a Partner and Managing Director of Goldman Sachs Group Inc (2007-2009), Chief Financial Officer of AstraZeneca plc (1997-2007) and a Partner of KPMG (1992-1997). In 2014, he was appointed an independent non-executive Director of HSBC Holdings plc and Chairman of HSBC’s European subsidiary, HSBC Bank plc. He is a non-executive Director ... 

Darin Weber, PhD
Regulatory Affairs & Quality Management

Dr Weber, who has 18 years of experience in cellular and tissue-based regenerative medicine products, joined Mesoblast in 2011. He serves on the United States Pharmacopeia Expert Committee and on committees within the International Society for Cellular Therapy and Alliance for Regenerative Medicine. Before joining Mesoblast, he worked as a senior consultant at Biologics Consulting Group, Inc. from 2004. Prior to that, Dr Weber worked at the United States Food and Drug Administration (FDA) Center for Biologics Evaluation and Research as a regulatory management officer from 1996 to 1998, as a regulatory review officer from 1998 to 2003, and as the Chief of the Cellular Therapy Branch in the Office of Cellular, Tissue and Gene Therapies from 2002 to 2004. During his employment with the FDA, he held a Commission in the United States Public Health Service Commissioned Corps, with a rank of Lieutenant Commander at the conclusion of his service.

Darin Weber, PhD
Regulatory Affairs & Quality Management


Dr Weber, who has 18 years of experience in cellular and tissue-based regenerative medicine products, joined Mesoblast in 2011. He serves on the United States Pharmacopeia Expert Committee and on committees within the International Society for Cellular Therapy and Alliance for Regenerative Medicine. Before joining Mesoblast, he worked as a senior consultant at Biologics Consulting Group, Inc. from 2004. Prior to that, Dr Weber worked at the United States Food and Drug Administration (FDA) Cen... 

Share Price ASX: MSB  AUD 1.14 as of Dec 14, 2018